恒定型自然殺傷細胞在哮喘中的研究進展_Chinese Journal of Respiratory and Critical Care Medicine

Authors：

陳甜甜 ,  時國朝

上海交通大學醫學院附屬瑞金醫院呼吸科（上海 200000）;

Corresponding?author：

時國朝, Email: shi_guochao@yahoo.com

Keywords：

DOI：

10.7507/1671-6205.2015130

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Citation： 陳甜甜, 時國朝. 恒定型自然殺傷細胞在哮喘中的研究進展. Chinese Journal of Respiratory and Critical Care Medicine, 2015, 14(5): 524-528. doi: 10.7507/1671-6205.2015130 Copy

1.	Akbari O, Faul JL, Hoyte EG, et al. CD4⁺ invariant T-cell receptor⁺ natural killer T cells in bronchial asthma. N Engl J Med, 2006, 354:1117-1129.
2.	Seddon Y, Thomas, Yung H, et al. NKT cells are not the predominant T cell in asthma and likely modulate, not cause, asthma. J Allergy Clin Immunol, 2010, 125:980-984.
3.	Akbari O, Stock P, Meyer E, et al. Essential role of NKT cells producing IL-4 and IL-13 in the development of allergen-induced airway hyperreactivity. Nat Med, 2003, 9:582-588.
4.	Hachem P, Lisbonne M, Michel ML, et al.α-Galactosylceramide-induced iNKT cells suppress experimental allergic asthma in sensitized mice:role of IFN-γ. Eur J Immunol, 2005, 35:2793-2802.
5.	Kronenberg M, Gapin L. The unconventional lifestyle of NKT cells. Nat Rev Immunol, 2002, 2:5575-5568.
6.	Bienemann K, Iouannidou K, Schoenberg K, et al. iNKT cell frequency in peripheral blood of Caucasian children and adolescent:the absolute iNKT cell count is stable from birth to adulthood. Scand J Immunol, 2010, 74:406-411.
7.	Montoya CJ, Pollard D, Martinson J, et al. Characterization of human invariant natural killer T subsets in health and disease using a novel invariant natural killer T cell-clonotypic monoclonal antibody, 6B11. Immunology, 2007, 122:1-14.
8.	Lisbonne M, Leite-de-Moraes MC. Invariant Va14 NKT lymphocytes:a double-edged immuno-regulatory T cell population. Eur Cytokine Netw, 2003, 14:4-14.
9.	Godfrey DI, Kronenberg M. Going both ways:immune regulation via CD1d-dependent NKT cells. J Clin Invest, 2004, 114:1379-1388.
10.	Kronenberg M. Toward an understanding of NKT cell biology:progress and paradoxes. Annu Rev Immunol, 2005, 23:877-900.
11.	Kawano T, Cui J, Koezuka, Y, et al. CD1d-restricted and TCR-mediated activation of vα14 NKT cells by glycosylceramides. Science, 1997, 278:1626-1629.
12.	Mendiratta SK, Martin WD, Hong S, et al. CD1d1 mutant mice are deficient in natural T cells that promptly produce IL-4. Immunity, 1997, 6:469-477.
13.	Cui JQ, Watanabe N, Kawano T, et al. Inhibition of T helper cell type 2 cell differentiation and immunoglobulin E response by ligand-activated Vα14 natural killer T cells. J Exp Med, 1999, 190:783-792.
14.	Van Kaer L, Parekh VV, Wu L. Invariant natural killer T cells:bridging innate and adaptive immunity. Cell Tissue Res, 2010, 343:43-55.
15.	Thomas SY, Chyung YH, Luster AD. CD4⁺ invariant T-cell-receptor⁺ natural killer T cells in bronchial asthma. J Allergy Clin Immunol, 2010, 125:980-984.
16.	Bendelac A, Savage PB, Teyton L. The biology of NKT cells. Annu Rev Immunol, 2007, 25:297-336.
17.	Lee YJ, Holzapfel KL, Zhu J, et al. Steady-state production of IL-4 modulates immunity in mouse strains and is determined by lineage diversity of INKT cells. Nat Immunol, 2013, 14:1146-1154.
18.	Brennan PJ, Brigl M, Brenner MB. Invariant natural killer T cells:an innate activation scheme linked to diverse effector functions. Nat Rev Immunol, 2013, 13:101-117.
19.	Lantz O, Bendelac A. An invariant T cell receptorαchain is used by a unique subset of major histocompatibility complex classⅠ-specific CD4⁺ and CD4^-8^- T cells in mice and humans. J Exp Med, 1994, 180:1097-1106.
20.	Chan SH, Cosgrove D, Waltzinger C, et al. Another view of the selective model of thymocyte selection. Cell, 1993, 73:225-236.
21.	Taniguchi M, Harada M, Kojo S, et al. The regulatory role of Vα14 NKT cells in innate and acquired immune response. Annu Rev Immunol, 2003, 21:483-513.
22.	Scneuplein F, Thariath A, Macdonald S, et al. A humanized monoclonal antibody specific for invariant natural killer T (iNKT) cells for in vivo depletion. PLoS One, 2013, 8(9):e76682.
23.	Borg NA, Wun KS, Kjer-Nielsen L, et al. CD1d lipid-antigen recognition by the semi-invariant NKT T-cell receptor. Nature, 2007, 448:44-49.
24.	Scott-Browne JP, Matsuda JL, Mallevaey T, et al. Germline-encoded recognition of diverse glycolipids by natural killer T cells. Nat Immunol, 2007, 8:1105-1113.
25.	Mallevaey T, Scott-Browne JP, Matsuda JL, et al. T cell receptor CDR2βand CDR3βloops collaborate functionally to shape the iNKT cell repertoire. Immunity, 2009, 31:60-71.
26.	Pellicci DG, Patel O, Kjer-Nielsen L, et al. Differential recognition of CD1d-α-galactosyl ceramide by the Vβ8.2 and Vβ7 semi-invariant NKT T cell receptors. Immunity, 2009, 31:47-59.
27.	Akbari O, Stock P, Meyer EH, et al. ICOS/ICOSL interaction is required for CD4⁺ invariant NKT cell function and homeostatic survival. J Immunol, 2008, 180:5448-5456.
28.	Burdin N, Brossay L, Koezuka Y, et al. Selective ability of mouse CD1 to present glycolipids:α-galactosylceramide specifically stimulates Vα14⁺NK T lymphocytes. J Immunol, 1998, 161:3271-3281.
29.	Brigl M, Brenner MB. How invariant natural killer T cells respond to infection by recognizing microbial or endogenous lipid antigens. Semin Immunol, 2010, 22:79-86.
30.	Centers for Disease Control and Prevention (CDC). Forecasted state-specific estimates of self-reported asthma prevalence-United States, 1998. Morb Mortal Wkly Rep, 1998, 47:1022-1025.
31.	Wills-Karp M. Immunologic basis of antigen-induced airway hyperresponsiveness. Annu Rev Immunol, 1999, 17:255-281.
32.	Grünig G, Warnock M, Wakil AE, et al. Requirement for IL-13 independently of IL-4 in experimental asthma. Science, 1998, 282:2261-2263.
33.	Wills-Karp M, Luyimbazi J, Xu X, et al. Interleukin-13:central mediator of allergic asthma. Science, 1998, 282:2258-2261.
34.	Robinson DS, Hamid Q, Ying S, et al. Predominant TH2-like bronchoalveolar T-lymphocyte population in atopic asthma. N Engl J Med, 1992, 326:298-304.
35.	Matsuda H, Suda T, Sato J, et al.α-Galactosylceramide, a ligand of natural killer T cells, inhibits allergic airway inflammation. Am J Respir Cell Mol Biol, 2005, 33:22-31.
36.	Lombardi V, Stock P, Singh AK, et al. a CD1d-dependent antagonist inhibits the activation of invariant NKT cells and prevents development of allergen-induced airway hyperreactivity. J Immunol, 2010, 184:2107-2115.
37.	Li L, Xia YY, Nguyen A, et al. Effects of Th2 cytokines on chemokine expression in the lung:IL-13 potently induces eotaxin expression by airway epithelial cells. J Immunol, 1999, 162:2477-2487.
38.	Matsukura S, Stellato C, Georas SN, et al. Interleukin-13 upregulates eotaxin expression in airway epithelial cells by a STAT6-dependent mechanism. Am J Respir Cell Mol Biol, 2001, 24:755-761.
39.	Chuang YH, Wang TC, Jen HY, et al.α-Galactosylceramide-induced airway eosinophilia is mediated through the activation of NKT cells. J Immunol, 2011, 186:4687-4692.
40.	Lisbonne M, Diem S, de Castro Keller A, et al. Cutting edge:invariant Vα14 NKT cells are required for allergen-induced airway inflammation and hyperreactivity in an experimental asthma model. J Immunol, 2003, 171:1637-1641.
41.	Akbari O, Stock P, Singh AK, et al. PD-L1 and PD-L2 modulate airway inflammation and iNKT-cell-dependent airway hyperreactivity in opposing directions. Mucosal Immunol, 2010, 3:81-91.
42.	Rothenberg ME, Hogan SP. The eosinophil. Annu Rev Immunol, 2006, 24:147-174.
43.	Koh YI, Shim JU. Association between sputum natural killer T cells and eosinophilic airway inflammation in human asthma. Int Arch Allergy Immunol, 2010, 153:239-248.
44.	Shim JU, Koh YI. Increased Th2-like invariant natural killer T cells in peripheral blood from patients with asthma. Allergy Asthma Immunol Res, 2014, 6:444-448.
45.	Carpio-Pedroza JC, Vaughan G, del Rio-Navarro BE, et al. Participation of CD161(+) and invariant natural killer T cells in pediatric asthma exacerbations. Allergy Asthma Proc, 2013, 34:84-92.
46.	Morishima Y, Ishii Y, Kimura T, et al. Suppression of eosinophilic airway inflammation by treatment withα-galactosylceramide. Eur J Immunol, 2005, 35:2803-2814.
47.	Grela F, Aumeunier A, Bardel E, et al. The TLR7 agonist R848 alleviates allergic inflammation by targeting invariant NKT cells to produce IFN-γ. J Immunol, 2011, 186:284-290.
48.	Scheuplein F, Thariath A, Macdonald S, et al. A humanized monoclonal antibody specific for invariant natural killer T (iNKT) cells for in vivo depletion. PLoS One, 2013, 8:e76692.

1. Akbari O, Faul JL, Hoyte EG, et al. CD4⁺ invariant T-cell receptor⁺ natural killer T cells in bronchial asthma. N Engl J Med, 2006, 354:1117-1129.
2. Seddon Y, Thomas, Yung H, et al. NKT cells are not the predominant T cell in asthma and likely modulate, not cause, asthma. J Allergy Clin Immunol, 2010, 125:980-984.
3. Akbari O, Stock P, Meyer E, et al. Essential role of NKT cells producing IL-4 and IL-13 in the development of allergen-induced airway hyperreactivity. Nat Med, 2003, 9:582-588.
4. Hachem P, Lisbonne M, Michel ML, et al.α-Galactosylceramide-induced iNKT cells suppress experimental allergic asthma in sensitized mice:role of IFN-γ. Eur J Immunol, 2005, 35:2793-2802.
5. Kronenberg M, Gapin L. The unconventional lifestyle of NKT cells. Nat Rev Immunol, 2002, 2:5575-5568.
6. Bienemann K, Iouannidou K, Schoenberg K, et al. iNKT cell frequency in peripheral blood of Caucasian children and adolescent:the absolute iNKT cell count is stable from birth to adulthood. Scand J Immunol, 2010, 74:406-411.
7. Montoya CJ, Pollard D, Martinson J, et al. Characterization of human invariant natural killer T subsets in health and disease using a novel invariant natural killer T cell-clonotypic monoclonal antibody, 6B11. Immunology, 2007, 122:1-14.
8. Lisbonne M, Leite-de-Moraes MC. Invariant Va14 NKT lymphocytes:a double-edged immuno-regulatory T cell population. Eur Cytokine Netw, 2003, 14:4-14.
9. Godfrey DI, Kronenberg M. Going both ways:immune regulation via CD1d-dependent NKT cells. J Clin Invest, 2004, 114:1379-1388.
10. Kronenberg M. Toward an understanding of NKT cell biology:progress and paradoxes. Annu Rev Immunol, 2005, 23:877-900.
11. Kawano T, Cui J, Koezuka, Y, et al. CD1d-restricted and TCR-mediated activation of vα14 NKT cells by glycosylceramides. Science, 1997, 278:1626-1629.
12. Mendiratta SK, Martin WD, Hong S, et al. CD1d1 mutant mice are deficient in natural T cells that promptly produce IL-4. Immunity, 1997, 6:469-477.
13. Cui JQ, Watanabe N, Kawano T, et al. Inhibition of T helper cell type 2 cell differentiation and immunoglobulin E response by ligand-activated Vα14 natural killer T cells. J Exp Med, 1999, 190:783-792.
14. Van Kaer L, Parekh VV, Wu L. Invariant natural killer T cells:bridging innate and adaptive immunity. Cell Tissue Res, 2010, 343:43-55.
15. Thomas SY, Chyung YH, Luster AD. CD4⁺ invariant T-cell-receptor⁺ natural killer T cells in bronchial asthma. J Allergy Clin Immunol, 2010, 125:980-984.
16. Bendelac A, Savage PB, Teyton L. The biology of NKT cells. Annu Rev Immunol, 2007, 25:297-336.
17. Lee YJ, Holzapfel KL, Zhu J, et al. Steady-state production of IL-4 modulates immunity in mouse strains and is determined by lineage diversity of INKT cells. Nat Immunol, 2013, 14:1146-1154.
18. Brennan PJ, Brigl M, Brenner MB. Invariant natural killer T cells:an innate activation scheme linked to diverse effector functions. Nat Rev Immunol, 2013, 13:101-117.
19. Lantz O, Bendelac A. An invariant T cell receptorαchain is used by a unique subset of major histocompatibility complex classⅠ-specific CD4⁺ and CD4^-8^- T cells in mice and humans. J Exp Med, 1994, 180:1097-1106.
20. Chan SH, Cosgrove D, Waltzinger C, et al. Another view of the selective model of thymocyte selection. Cell, 1993, 73:225-236.
21. Taniguchi M, Harada M, Kojo S, et al. The regulatory role of Vα14 NKT cells in innate and acquired immune response. Annu Rev Immunol, 2003, 21:483-513.
22. Scneuplein F, Thariath A, Macdonald S, et al. A humanized monoclonal antibody specific for invariant natural killer T (iNKT) cells for in vivo depletion. PLoS One, 2013, 8(9):e76682.
23. Borg NA, Wun KS, Kjer-Nielsen L, et al. CD1d lipid-antigen recognition by the semi-invariant NKT T-cell receptor. Nature, 2007, 448:44-49.
24. Scott-Browne JP, Matsuda JL, Mallevaey T, et al. Germline-encoded recognition of diverse glycolipids by natural killer T cells. Nat Immunol, 2007, 8:1105-1113.
25. Mallevaey T, Scott-Browne JP, Matsuda JL, et al. T cell receptor CDR2βand CDR3βloops collaborate functionally to shape the iNKT cell repertoire. Immunity, 2009, 31:60-71.
26. Pellicci DG, Patel O, Kjer-Nielsen L, et al. Differential recognition of CD1d-α-galactosyl ceramide by the Vβ8.2 and Vβ7 semi-invariant NKT T cell receptors. Immunity, 2009, 31:47-59.
27. Akbari O, Stock P, Meyer EH, et al. ICOS/ICOSL interaction is required for CD4⁺ invariant NKT cell function and homeostatic survival. J Immunol, 2008, 180:5448-5456.
28. Burdin N, Brossay L, Koezuka Y, et al. Selective ability of mouse CD1 to present glycolipids:α-galactosylceramide specifically stimulates Vα14⁺NK T lymphocytes. J Immunol, 1998, 161:3271-3281.
29. Brigl M, Brenner MB. How invariant natural killer T cells respond to infection by recognizing microbial or endogenous lipid antigens. Semin Immunol, 2010, 22:79-86.
30. Centers for Disease Control and Prevention (CDC). Forecasted state-specific estimates of self-reported asthma prevalence-United States, 1998. Morb Mortal Wkly Rep, 1998, 47:1022-1025.
31. Wills-Karp M. Immunologic basis of antigen-induced airway hyperresponsiveness. Annu Rev Immunol, 1999, 17:255-281.
32. Grünig G, Warnock M, Wakil AE, et al. Requirement for IL-13 independently of IL-4 in experimental asthma. Science, 1998, 282:2261-2263.
33. Wills-Karp M, Luyimbazi J, Xu X, et al. Interleukin-13:central mediator of allergic asthma. Science, 1998, 282:2258-2261.
34. Robinson DS, Hamid Q, Ying S, et al. Predominant TH2-like bronchoalveolar T-lymphocyte population in atopic asthma. N Engl J Med, 1992, 326:298-304.
35. Matsuda H, Suda T, Sato J, et al.α-Galactosylceramide, a ligand of natural killer T cells, inhibits allergic airway inflammation. Am J Respir Cell Mol Biol, 2005, 33:22-31.
36. Lombardi V, Stock P, Singh AK, et al. a CD1d-dependent antagonist inhibits the activation of invariant NKT cells and prevents development of allergen-induced airway hyperreactivity. J Immunol, 2010, 184:2107-2115.
37. Li L, Xia YY, Nguyen A, et al. Effects of Th2 cytokines on chemokine expression in the lung:IL-13 potently induces eotaxin expression by airway epithelial cells. J Immunol, 1999, 162:2477-2487.
38. Matsukura S, Stellato C, Georas SN, et al. Interleukin-13 upregulates eotaxin expression in airway epithelial cells by a STAT6-dependent mechanism. Am J Respir Cell Mol Biol, 2001, 24:755-761.
39. Chuang YH, Wang TC, Jen HY, et al.α-Galactosylceramide-induced airway eosinophilia is mediated through the activation of NKT cells. J Immunol, 2011, 186:4687-4692.
40. Lisbonne M, Diem S, de Castro Keller A, et al. Cutting edge:invariant Vα14 NKT cells are required for allergen-induced airway inflammation and hyperreactivity in an experimental asthma model. J Immunol, 2003, 171:1637-1641.
41. Akbari O, Stock P, Singh AK, et al. PD-L1 and PD-L2 modulate airway inflammation and iNKT-cell-dependent airway hyperreactivity in opposing directions. Mucosal Immunol, 2010, 3:81-91.
42. Rothenberg ME, Hogan SP. The eosinophil. Annu Rev Immunol, 2006, 24:147-174.
43. Koh YI, Shim JU. Association between sputum natural killer T cells and eosinophilic airway inflammation in human asthma. Int Arch Allergy Immunol, 2010, 153:239-248.
44. Shim JU, Koh YI. Increased Th2-like invariant natural killer T cells in peripheral blood from patients with asthma. Allergy Asthma Immunol Res, 2014, 6:444-448.
45. Carpio-Pedroza JC, Vaughan G, del Rio-Navarro BE, et al. Participation of CD161(+) and invariant natural killer T cells in pediatric asthma exacerbations. Allergy Asthma Proc, 2013, 34:84-92.
46. Morishima Y, Ishii Y, Kimura T, et al. Suppression of eosinophilic airway inflammation by treatment withα-galactosylceramide. Eur J Immunol, 2005, 35:2803-2814.
47. Grela F, Aumeunier A, Bardel E, et al. The TLR7 agonist R848 alleviates allergic inflammation by targeting invariant NKT cells to produce IFN-γ. J Immunol, 2011, 186:284-290.
48. Scheuplein F, Thariath A, Macdonald S, et al. A humanized monoclonal antibody specific for invariant natural killer T (iNKT) cells for in vivo depletion. PLoS One, 2013, 8:e76692.

Previous Article
Epac在哮喘氣道重塑中的作用及機制

Chinese Journal of Respiratory and Critical Care Medicine

恒定型自然殺傷細胞在哮喘中的研究進展

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Format

Content